Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc最新文献

{"title":"Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms.","authors":"Albert E Zant, Xavier A Figueroa, Christopher P Paulson, James K Wright","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>SARs-Cov-2 infections can produce prolonged illness and significant disability. Patients recovering from COVID-19 can have persistent symptoms leading to long-term morbidity.</p><p><strong>Methods: </strong>Six patients with long-lasting (> 30 days) COVID-19 symptoms were treated with hyperbaric oxygen (HBO2) therapy. All patients were assessed for symptoms using the ImPACT questionnaire, a muscle and joint pain scale, and a modified Borg dyspnea scale. Patients were assessed before, during and after HBO2 treatments.</p><p><strong>Results: </strong>All patients saw improvements in the measured symptoms to levels that were the same as pre-infection levels (five of six patients) or had significant improvement in symptoms (one patient).</p><p><strong>Conclusion: </strong>The results suggest that HBO2 helped to improve symptom scores, reduce the length of time of symptoms, and improved the quality of life. More detailed and randomized studies are needed to confirm the results in this report.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"333-339"},"PeriodicalIF":0.7,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40438537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk assessment in divers: Toward safer diving.","authors":"Rienk Rienks,&nbsp;Mattijn Buwalda,&nbsp;Jeroen Bucx,&nbsp;Emile Dubois,&nbsp;Thijs Wingelaar,&nbsp;Rob van Hulst","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Similar to aviation, diving is performed in an environment in which acute incapacitation may lead to a fatal outcome. In aeromedicine, a pilot is considered \"unfit to fly\" when the cardiovascular event risk exceeds one percent per annum, the so-called 1% rule. In diving no formal limits to cardiovascular risk have been established. Cardiovascular risk of divers can be calculated using the modified Canadian Cardiovascular Society (CCS) Risk of Harm formula: risk of harm (RH: cardiovascular fatality rate per year during diving: number × 10-⁵/divers/year) = time diving (TD: number of dives × 10-⁴) × sudden cardiac incapacitation (SCI: cardiovascular diver event rate per year (number × 10-⁵/year). The SCI and thus the RH are strongly dependent on age. Using the CCS criterion for RH, 5 × 10-⁵ divers/year, and considering an average of 25 dives per year per diver, the calculated maximum acceptable SCI is 2%/year, consistent with current practice for dive medical examinations. If the SCI were to exceed 2%/year, a diver could be considered \"unfit to dive,\" which could particularly benefit older (≥ 50 years) divers, in whom cardiovascular risk factors are often not properly treated. For the prevention of fatal diving accidents due to atherosclerotic cardiovascular disease, a dive medical examination is of limited value for young (≺ 50 years) divers who have no cardiovascular risk factors. Introducing a cardiovascular risk management system for divers may achieve a reduction in fatal diving accidents that result from cardiovascular disease in older divers engaged in both recreational and professional diving.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"355-365"},"PeriodicalIF":0.9,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40438539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of hyperbaric oxygen therapy on gene expression: microarray analysis on wound healing.","authors":"Jakub Tlapák,&nbsp;Petr Chmátal,&nbsp;Boris Oniscenko,&nbsp;Vojtech Pavlík,&nbsp;Petr Dosel,&nbsp;Jirí Páral,&nbsp;Petr Lochman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Hyperbaric oxygen (HBO2) therapy can have a positive effect on wound healing, angiogenesis and blood flow. No prior study has described the effects of HBO2 therapy and gene expression of this process. The goal of our research was to show the effects of HBO2 and its impact at the molecular level on angiogenesis, proliferation, differentiation, oxidative stress, inflammation, and extracellular matrix formation. Live animal subjects were used for simulating the process of wound healing under standard conditions and under the influence of HBO2.</p><p><strong>Methods: </strong>Two experimental groups were created using injured rabbits (N=24), one group (N=12) treated with hyperbaric therapy twice a day and one (N=12) with standard wound care management. Wounds were surgical, uninfected, and in healthy animal test subjects. We compared the whole genomic analysis of the transcriptome with the use of microarray technology at three intervals during treatment.</p><p><strong>Results: </strong>The induction of the wounds in rabbit skin increased expression of hundreds of genes in both treatment groups. The numbers of elevated and decreased genes gradually reduced as the wound healed. Gene expression analysis showed elevated expression of several genes associated with inflammation in both groups of injured animals. Genes connected to the process of angiogenesis, proliferation, differentiation, oxidative stress and extracellular matrix formation were without statistically significant changes.</p><p><strong>Conclusion: </strong>The evidence did not support that HBO2 had any significant effect on gene expression during wound healing. Additionally, there was no evidence to support that there were changes in gene expression in either treatment group.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"31-37"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37741390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study of decompression sickness using recorded depth-time profiles.","authors":"Richard G Dunford,&nbsp;Petar D Denoble,&nbsp;Robert Forbes,&nbsp;Carl F Pieper,&nbsp;Laurens E Howle,&nbsp;Richard D Vann","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>122,129 dives by 10,358 recreational divers were recorded by dive computers from 11 manufacturers in an exploratory study of how dive profile, breathing gas (air or nitrox [N2/O2] mixes), repetitive diving, gender, age, and dive site conditions influenced observed decompression sickness (DCSobs). Thirty-eight reports were judged as DCS. Overall DCSobs was 3.1 cases/10⁴ dives.</p><p><strong>Methods: </strong>Three dive groups were studied: Basic (live-aboard and shore/dayboat), Cozumel Dive Guides, and Scapa Flow wreck divers. A probabilistic decompression model, BVM(3), controlled dive profile variability. Chi-squared test, t-test, logistic regression, and log-rank tests evaluated statistical associations.</p><p><strong>Results: </strong>(a) DCSobs was 0.7/10⁴ (Basic), 7.6/10⁴ (Guides), and 17.3/104 (Scapa) and differed after control for dive variability (p ≺ 0.001). (b) DCSobs was greater for 22%-29% nitrox (12.6/10⁴) than for 30%-50% nitrox (2.04/10⁴) (p ≤ 0.0064) which did not differ from air (2.97/1010⁴). (c) For daily repetitive dives (≺12-hour surface intervals (SI)), DCS occurred only following one or two dives (4.3/1010⁴ DCSobs; p ≺ 0.001) where SIs were shorter than after three or more dives. (d) For multiday repetitive dives (SIs ≺ 48 hours), DCS was associated with high multiday repetitive dive counts only for Guides (p = 0.0018). (e) DCSobs decreased with age at 3%/year (p ≤ 0.0144). (f) Males dived deeper (p ≺ 0.001) but for less time than females (p ≺ 0.001).</p><p><strong>Conclusion: </strong>Collecting dive profiles with dive computers and controlling for profile variability by probabilistic modeling was feasible, but analytical results require independent confirmation due to limited observed DCS. Future studies appear promising if more DCS cases are gathered, stakeholders cooperate, and identified data collection problems are corrected.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"75-91"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A discussion about bentonite: Response","authors":"Owen O'Neill,&nbsp;Justin Costello,&nbsp;John Sullivan,&nbsp;Lisa Castillon","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"172-174"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of a continuous glucose monitoring device during hyperbaric exposure.","authors":"Chae Bliss,&nbsp;Enoch Huang,&nbsp;Davut Savaser","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Hyperbaric oxygen therapy has been demonstrated to lower blood glucose levels in patients with diabetes. Continuous glucose monitoring (CGM) allows glucose monitoring in real time. Battery-operated CGM transmitters have yet to be formally tested and given safety approval for use in a hyperbaric environment.</p><p><strong>Materials and methods: </strong>We evaluated and tested commercially available Dexcom® G6 CGM transmitters under hyperbaric conditions. Each transmitter contains a 3V, 130-mAh (0.39 Wh) lithium manganese dioxide battery (IEC CR1632) and circuit board that are fully encapsulated in epoxy. Each transmitter is pressurized to 90 pounds per square inch (psi) in an autoclave at 40°C for up to 72 hours during manufacturing to ensure that all enclosed air spaces are eliminated from the epoxy. We compared the CGM components against section 14.2.9.3.17.5 of the 2018 National Fire Protection Association 99 (NFPA 99) Health Care Facilities Code requirements. Six CGM transmitters attached to estimated glucose value generators (EGVGs) underwent 11 pressurization cycles to 45 feet of seawater (fsw). All transmitters were returned to the manufacturer to assess post-exposure structural integrity. G6 sensors, which contain no electrical components or compressible air spaces, do not pose a risk in the hyperbaric environment.</p><p><strong>Results: </strong>There was no observed change in preset EGVG readings during hyperbaric exposures. Post-exposure testing revealed no structural compromise after repeated hyperbaric exposures.</p><p><strong>Conclusions: </strong>The CGM transmitter meets section 14.2.9.3.17.5 of the 2018 NFPA 99 requirements for battery-operated devices allowed for use in a hyperbaric environment. This analysis revealed no significant safety concerns with subjecting Dexcom G6 CGM transmitters to hyperbaric environments.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"13-19"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37741388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygenation protects the kidney against ischemia-reperfusion injury.","authors":"Milan Ivanov,&nbsp;Predrag Brkic,&nbsp;Una-Jovana Vajic,&nbsp;Nevena Mihailovic-Stanojevic,&nbsp;Davorka Milacic,&nbsp;Djurdjica Jovovic,&nbsp;Danijela Karanovic,&nbsp;Marina Djelic,&nbsp;Rada Jeremic,&nbsp;Zoran Miloradovic","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) as a consequence of ischemia is a common clinical event that can lead to unacceptably high morbidity and mortality. Hyperbaric oxygen (HBO2) preconditioning has been shown to prevent ischemia-reperfusion injury (IRI) in different tissues.</p><p><strong>Objectives: </strong>The aim of our study was to compare the effects of HBO2 preconditioning on renal hemodynamics, kidney function and oxidative stress in normotensive and spontaneously hypertensive rats that suffered kidney IRI.</p><p><strong>Methods: </strong>An experiment was performed on Wistar (normotensive) and spontaneously hypertensive rats (SHR). The animals were divided into the following experimental groups: sham-operated rats and rats with or without HBO2 preconditioning 24 hours before post-ischemic AKI induction. Treated rats were placed into experimental HBO2 chambers and exposed to pure oxygen twice a day for two consecutive days (2.026 bar of oxygen) for 60 minutes. AKI was performed the next morning. The right kidney was removed and the renal ischemia was performed by clamping the left renal artery for 45 minutes.</p><p><strong>Results: </strong>In this study, HBO2 preconditioning significantly improved disturbed renal hemodynamics, major markers of kidney function in plasma (creatinine, urea and phosphate) as well as antioxidant enzymes (superoxide dismutase and catalase) activities in erythrocytes after AKI induction. Also, HBO2 preconditioning decreased lipid peroxidation in plasma after ischemic AKI. Positive effects were observed in both strains of rats.</p><p><strong>Conclusions: </strong>Our results suggest that HBO2 treatment improves renal hemodynamic and kidney function and decreases oxidative stress of Wistar and SHR rats with an AKI episode. Furthermore, it also implies that pre-existing hypertension does not affect the beneficial effects of HBO2 preconditioning.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"21-30"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37741389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of hyperbaric oxygen therapy on idiopathic sudden sensorineural hearing loss.","authors":"Bekir Selim Bagli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Idiopathic sudden sensorineural hearing loss (ISSHL) is defined as unexplained hearing loss of at least 30 decibels (dB) occurring within 72 hours over at least three contiguous frequencies. ISSHL is common and has a significant effect on quality of life. Hyperbaric oxygen (HBO2) therapy is a medical treatment method that aims to increase the level of dissolved oxygen in the tissues. Correcting perilymph hypoxia is the goal of HBO2 therapy for ISSHL. In recent years, HBO2 therapy has been increasingly involved in the treatment of ISSHL. The medical records of 135 patients who had received HBO2 therapy for ISSHL were reviewed. Demographic properties of patients, severity of hearing loss, delay until HBO2 therapy, number of HBO2 therapy sessions and outcomes were evaluated. Findings of the present study are similar to most of previous studies that demonstrate that HBO2 therapy as adjunctive treatment results in an improvement of hearing. Early treatment is important for ISSHL, and HBO2 therapy is recommended in the early period, particularly within 14 days of onset.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"51-56"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen therapy in patients suffering from wounds in calciphylaxis: a narrative review.","authors":"Diana A Charaghvandi,&nbsp;David N Teguh,&nbsp;Rob A van Hulst","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Calcific uremic arteriolopathy (calciphylaxis) is a rare and highly lethal vascular disease. Vascular calcification with calcium depositions lead to ischemic ulcers associated with gangrene, severe pain and poor healing. Although hyperbaric oxygen (HBO2) therapy has been used in the treatment of calciphylaxis, evidence of its effectiveness is limited.</p><p><strong>Objective: </strong>To determine whether HBO2 therapy has a beneficial effect in the healing of calciphylaxis ulcers.</p><p><strong>Methods: </strong>A search was made in PubMed using a comprehensive strategy to identify the effect of HBO2 on calciphylaxis wounds. Included in the analysis were studies published up to October 2018 involving a minimum of four patients receiving HBO2 therapy.</p><p><strong>Results: </strong>Ten retrospective (case) series were included. This review included a total of 131 patients with calciphylaxis who were treated with HBO2 therapy; of these, 58 patients (45%) had full response on HBO2 with complete wound closure. Regarding partial response, 17 of the patients (13%) experienced substantial wound improvement on different wound scale scores.</p><p><strong>Conclusion: </strong>Patients with calcific uremic arteriolopathy can benefit from HBO2. More research is needed using standardized wound scores. Outcomes related to quality of life and pain relief should also be assessed.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"111-123"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen for refractory hemorrhagic cystitis after stem cell transplantation: case report.","authors":"Kanwaljeet Maken,&nbsp;David K Bland","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (AHSCT) in both children and adults has been associated with significant morbidity and mortality. Early HC can occur within 48 hours of completing the chemotherapy conditioning regimen, is usually associated with agents such as cyclophosphamide, and generally resolves promptly. Late HC is commonly associated with BK and other viruses and can prove refractory to antiviral and supportive therapy. There are limited reports of hyperbaric oxygen (HBO2) therapy showing benefit for refractory HC cases. We describe our experience with salvage HBO2 for a 15-year-old male with refractory HC beginning one month post AHSCT and associated with BK virus. Despite supportive therapies including hyperhydration, forced diuresis, transfusions, intravenous and intravesical cidofovir, macroscopic hematuria persisted and resulted in post-obstructive acute renal failure, need for a suprapubic catheter, then bilateral percutaneous nephrostomy tubes. HBO2 was started two months after the AHSCT and one month after detection of BK viremia. In the week prior to starting HBO2 therapy the patient required transfusion with 25 units of red blood cells and seven units of platelets. After HBO2 was started his transfusion requirements progressively decreased, and he had return of renal function. He had no adverse effect from the HBO2. HBO2 therapy could thus be useful in controlling refractory HC after AHSCT.</p>","PeriodicalId":520823,"journal":{"name":"Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc","volume":" ","pages":"125-129"},"PeriodicalIF":0.9,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}